Written by ι Stock Market Media Group Staff — September 4, 2013
Plandaí Biotechnology, Inc. (OTCQB: PLPL) is already hard at work in Africa to develop a treatment for malaria, and it may just have a product in its Phytofare™ Catechin Complex that can address the continent’s diabetes epidemic as well. With diabetes dramatically on the rise worldwide, the numbers are grim everywhere and no country, region or continent is being spared from the disease.
According to the International Diabetes Federation there are more than 370 million diabetics worldwide and another 190 million who are living with the disease but remain undiagnosed.
The World Health Organization expects that by 2020 the largest increases in non-communicable disease deaths like cancer and diabetes will be seen in Africa. Professor Bongani Mayosi, the head of medicine at Groote Schuur Hospital in South Africa, said Africa’s diabetes statistics are alarming. “In 2008, the continent had 27-million diabetics, or 7.5% of the world’s total diabetes population; by 2030 that figure is expected to reach 50-million.”
Enter Plandaí Biotechnology, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, and a company that has set up shop in South Africa to deliver highly bioavailable products to market. In 2011, Plandaí, through its subsidiaries, entered into a 49-year notarial lease on 8,000 acres of tea plantation in Mpumalanga province of South Africa.
The lease gives Plandaí access to green tea, and other fruits for use in its botanical extracts. This is essential because the company’s extraction process is the key to delivering highly bioavailable products and that process requires the use of “live” plant material—meaning the plant matter must be processed within hours of harvest.
Plandaí feels is it producing products that can make a difference in the fight against diabetes. The company’s Phytofare™ Catechin Complex is one of those candidates. Most of the data Plandaí currently possesses comes from in-vitro studies and third party clinical trials since its product is simply too new to have generated sufficient comparable in-house animal and human data. The company is actively involved in multiple clinical trials that should shed greater light on the effectiveness of higher bioavailability.
With that being said, green tea catechins (specifically EGCG) have been well documented to induce weight loss through a process called “thermogenesis” which essentially increases the metabolic rate allowing more fat to be burned. There is further evidence to suggest that the method of action is ketosis, similar to what is experience from a high-protein diet such as Atkins, etc. So, high dosages of green tea catechins will enable the body to burn fat while preserving lean muscle mass.
Unfortunately, the dosage necessary to achieve these results in humans often exceeds desired levels and causes unwanted side effects such as nausea. Plandaí executives believe that the company’s Phytofare™ catechin product will overcome these issues because lower dosages can be used to generate much higher bioavailability.
The question remains, what effect will this product have on diabetes? Very often, heart disease, high blood pressure, hypertension, and diabetes are by-products of obesity. Plandaí’s scientists anticipate that the use of Phytofare™ Catechin Complex will result in weight loss and correlative decreases in cholesterol levels, high blood pressure, and blood glucose levels, similar to the results achieved through a high-protein diet.
The company has commissioned a human clinical study with KGK Synergize in Canada to specifically address this matter. In this study they will be testing not only weight loss, but also performing a full blood and lipid panel to help determine the full range of physiologic changes from Phytofare.